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Abstract : The correlation between the efficacy of 4-weeks administration with 
pranlukast, leukotriene receptor antagonist, and LTs generation by peripheral leuko- 
cytes were evaluated in 18 patients with mild-persistent asthma. The efficacy of 
pranlukast administration was assessed by symptom, morning PEF and pulmonary 
function. Pranlukast were effective in 12/18(67%) patients. In those patients, LTC4 
generation before pranlukast administration was significantly high, compared with 
that in pranlukast-ineffective patients. LTC4 generation decreased after 4-weeks ad- 
ministration with pranlukast in effective patients. In ineffective patients, however, 
LTC4 generation increased after 4-weeks administration. LTB4 had shown no signifi- 
cant difference between effective and ineffective patients before administration, and 
LTB4 decreased after 4-weeks in both groups. Proport ion of peripheral eosinophi Is in 
effective patients were higher than that in ineffective patients, however not signifi- 
cant. After 4-weeks, proportion of eosinophi Is was decreased in effective patients and 
increased in ineffective patients. These findings suggest that pranlukast is effective 
for patients with high LTC4 generation and has the effect to suppress the accumula- 
tion of eosinophils in such patients. 
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Introduction 
The biological activities of LTs have an im- 
portant inflammatory role i n  several lung 
Leukotriene C4 (LTC4) are membrane- diseases, including a ~ t h m a ~ . ~ ) .  LTC4, and i ts  
derived lipid mediators derived from arachi- bioactive metabolites, LTD4 and LTE4 cause 
donic acid via the 5-lipoxygenase pathway". bronchial smooth muscle contraction i n  vitro, 
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prolonged bronchial contraction in vivo, and 
increased vascular permeability and increased 
mucus prod~ct ion ' .~) ,  a11 of which are charac- 
teristic features of the pathology of asthma. 
Several specific inhibitors of LT synthesis 
and LT receptor antagonists have been 
showed inhibitory effects t o  airway obstruc- 
tion induced by allergens, exercise and 
hyperventilation6. ". 
Pranlukast, a selective receptor antagonist 
of cysteinyl leukotrienes (LTC4, LTD4 and 
LTE4), has been shown t o  protect against the 
bronchial obstruction induced allergens. 
Pranlukast have also demonstrated efficacy 
in many patients with asthma8). However, a 
few asthmatics showed little o r  no improve- 
ment of asthma symptoms with pranlukast 
administrations. 
The present study investigated the correla- 
tion between efficacy of pranlukast for pa- 
tients with asthma and leukotriene generation 
by peripheral leukocyte. 
Method 
We studied 18 adults patients with mild- 
persistent asthma (13 females and 5 males ; 
mean age 54.3 years). Theophylline and /3 2- 
stimulator were administered t o  all patients, 
and inhaled beclomethasone t o  4 patients. 
No patients took systemic administration of 
corticosteroid. 
After giving informed consent, patients re- 
ceived 225mg of Pranlukast (Ono Pharm. Co. 
Ltd., Osaka, Japan) twice daily for 4-weeks. 
During 4-weeks, patients were asked t o  record 
symptoms in their diaries and t o  monitor 
changes in the PEF in the morning using a 
peak flow meter (Mini-Wright) . Pulmonary 
function test were measured using a dry-seal 
spirometer (CHSTAC-33 ; Chest, Tokyo, Ja-  
pan) before and after 4-weeks administration 
of pranlukast. 
The generation of LTs by peripheral leuko- 
cytes was assessed by HPLC method. In 
brief, cells were separated by aqueous two- 
phase partition using dextran. The number 
of cells was then adjusted t o  5 x l O V m l  in 
Tris ACM and cell differentiation by Kimura- 
Tanizaki stains were undergone. The Ca 
ionophore A23187 (l p g )  was added to  the 
cell suspension and incubated for 15 min a t  
37°C. LTC4 and LTB4 were extracted using a 
C18 Seppak (Waters Associates, Milford, 
Mass., USA) and their concentrations were 
determined by HPLC (Model 510, equipped 
with an ultraviolet detector ; Waters Associ- 
ates). The results are expressed a s  nanograms 
per 5x106 cells. 
After 4 weeks, the efficacy of pranlukast 
were assessed by the changes of daily asthma 
symptoms, morning PEF and pulmonary 
functions. Then patients were devided into 
two groups, effective and ineffective group. 
The correlation of the efficacy of pranlukast 
and LTs generation by peripheral leukocytes 
were evaluated before and after 4 week. 
Resu I ts  
Pranlukast were effective in 12/18(67%) 
patients, and ineffective in 6/18(33%) pa- 
tients with asthma. No significant difference 
was seen between age or duration of asthma 
between effective and ineffective group. In 
effective group, morning PEF before 
pranlukast administration was lower than 
tha t  in ineffective group, however there was 
no significance. After &weeks, the PEF 
value increased in effective group. On the 
other hand, ineffective group had shown de- 
crease of morning PEF (Fig. l ) .  Regarding 
pulmonary function test, FVC were improved 
in effective and ineffective group after 4- 
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weeks. In ineffective group, however, in- 
crease of FVC was little. %FEV(predicted) 
had shown improvement in effective group 
after 4-weeks. On the other hand, in ineffec- 
tive group, %FEV(predicted) had shown de- 
crease after 4-weeks (Fig.2). 
Before pranlukast administration, the 
amount of LTC4 in effective group was sig- 
nificantly higher than that  in ineffective 
effectiw group 
T 
I ineffectiw group 
group. After $-weeks administration, LTC4 
50 4 
decreased in effective arouo. On the other I 
a 0 :  
hand, LTC4 increased in ineffective 
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Before After 
group(Fig.3). LTB4 had shown no signifi- 
cant difference between two groups before 
administration. After $-weeks, LTB4 was Fig.1. Changes of morning PEF after pran- 
decreased in both groups. lukast administration. PEF in effec- 
Blood eosinophils in effective group were tive group increased after 4-weeks ad- 
higher than that  in ineffective group before ministration. In ineffective group, PEF 
administration, however not significant. Af- decreased after $-weeks. 
ter Cweeks, eosinophils were decreased in ef- 
fective group and increased in ineffective 
group(Fig. 4). 
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Fig.2. Changes of FVC and FEVl before and after pranlukast administration. %FVC increased 
in effective and ineffective group after 4-weeks administration. %FEVl(predicted) 
increased in effective group after Cweeks adminitration, and decreased in ineffective 
group. 
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Fig.3 LTC4 generation by peripheral leuko- Fig.4. Changes of eosinophils proportion in 
cytes. LTC4 in effective group before peripheral leukocytes. Eosinophil proportion 
pranlukast administration was signifi- was high in effective group, compared t o  that  
cantly high, compared t o  that  in inef- in ineffective group, however not significant. 
fective group. after 4-weeks admini- Eosinophils in effective group decreased after 
stration, LTC4 decreased in effective 4-weeks and increased in ineffective group. 
group and increased in ineffective 
group. 
Discussion 
Bronchial asthma is widely recognized a s  a 
chronic inflammatory diseaseg'. Leukotrienes 
are potent proinflammtory mediators that  
appear t o  contribute to  pathophysiological 
features of asthma. That is  t o  say, con- 
traction of airway smooth muscle, increase 
of microvascular permiability, stimulation of 
mucus secretion, decrease of mucociliary 
clearance were observed by LTs1O). Our re- 
sults showed tha t  4-weeks administration 
with pranlukast improved asthma symptoms, 
morning PEF and pulmonary functions in 
67% of patients with asthma (effective 
group). This result suggests that  LTs are 
important factors for majority of patients 
with asthma. However, 33% of patients had 
shown no improvements by pranlukast 
administration in our study( (ineffective 
group). In ineffective group, LTC4 genera- 
tion by peripheral leukocytes was signifi- 
cantly lower than that  in effective group. 
This finding suggests that  pranlukast has low 
efficacy for patients with asthma whose LTs 
generation are weak and other chemical me- 
diators, such as  histamine,PAF and TXA2, 
have major roles in their asthma reaction. 
LTs are synthesized by inflammatory cells 
during an asthma reaction. LTC4 was gener- 
ated mainly by mast cells and eosinophilsl'). 
In peripheral blood, LTC4 was mostly gener- 
ated by eosinophils. Therefore, it is supposed 
that  LTC4 generation by peripheral leuko- 
cytes reflect the population of eosinophils. 
In our study, the population of eosinophils in 
effective group was higher than that  in inef- 
fective group before pranlukast admini- 
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stration. However, no significant difference 
was observed between two groups. Even 
now, measurements of LTs generation need 
many complicated processes. On the other 
hand, proportion of eosinophils is easily 
measurable. However, our results suggest 
that  i t  may be difficult to  predict the effi- 
cacy of pranlukast by the population of pe- 
ripheral eosinophils, because eosinophil popu- 
lation in effective group and tha t  in 
ineffective group overlapped largely. After 
4-weeks administration, population of 
eosinophils decreased in effective group. This 
result meant that  LTC4 and other chemical 
mediators which were generated or released 
by eosinophils might decrease by pranlukast 
administration. A major contributor t o  the 
damage in the airway of asthmatic patients 
is the eosinophil, which, upon activation, re- 
leases granule-associated cytotoxic, cationic 
proteins, including the major basic protein 
and eosinophil peroxidase, and membrane-de- 
rived de novo-synthesized bioactive lipid me- 
diators, including LTC4, LTD4 and LTE4, as  
well as  PAF. Accumulating evidence suggests 
that  leukotriene receptor antagonists includ- 
ing pranlukast may influence the accumula- 
tion and maintenance of eosinophilic re- 
sponses a t  the site of inflammation. 
Inhalation of LTE4 induced an increase in 
number of eosinophils and neutrophils in lam- 
ina propria of the airway in patients with 
asthma. The number of eosinophils were 10- 
fold greater than those of neutrophils. There 
was no significant change in numbers of lym- 
phocytes, plasma cells, mast cells or macro- 
phages'" . Other studies showed that  
leukotrienes induced specific migration of 
eosinophils in vitro'". In our study, however, 
population of eosinophils increased after 4- 
weeks in ineffective group. In such patients, 
other eosinophil-chemotactic factors are sup- 
posed t o  exist. 
For asthmatics whose LTC4 generation in- 
creased, our Results suggest that  pranlukast 
is a effective agent in improvements of daily 
asthmatic symptoms and pulmonary func- 
tions, and have effect t o  suppress the accu- 
mulation of eosinophils. 
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し，効果群，非効果群の2群に分類した．18例中  
12例（67％）の症例がプランルカスト投与により，  
臨床症状の軽減，ピークフロー値の増加，肺機能  
の改善が認められた．効果群におけるプラ▼ンルカ  
スト投与前のLTC4値は，非効果群のLTC4値に比  
較して有意に高値であった．4週間の投与後には  
効果群ではLTC4値は減少し，非効果群では増加  
した．両群のLTB4値はプランルカスト投与前で  
有意な差は認められず，投与後には両群で減少し  
た．投与前の好酸球分画は，効果群において非効  
果群に比べ高値であったが，有意な差は認められ  
なかった．4週間の投与後，効果群においては好  
酸球は減少し，非効果群においては増加した．以  
上の結果より，プランルカストは末梢血白血球の  
LTC4産生能が高い症例において効果的であり，  
好酸球集積を抑制する作用を有すると考えられる．   
気管支喘息症例における末梢血白血球のロイコト  
リエンC4産生能とロイコトリエン受容体括抗薬  
プランルカストの効果に関する検討  
御船尚志，高田真吾，岡本 誠，柘野浩史，  
芦田耕三，光延文裕，保崎泰弘，谷崎勝朗，  
原田実根1）  
岡山大学医学部附属病院三朝分院内科  
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軽症気管支喘息18例にロイコトリエン受容体桔  
抗薬プランルカストを4週間投与し，その効果と  
末梢血白血球からのLTC4，LTB4産生能の関係を  
検討した．プランルカストの効果は臨床症状，起  
床時ピークフロー値，肺機能の変化によって判定  
